BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 19330681)

  • 1. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
    Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
    Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
    Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
    Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden.
    Dansk V; Malmström PU; Bläckberg M; Malmenäs M
    Future Oncol; 2016; 12(8):1025-38. PubMed ID: 26975197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
    Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
    Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
    Witjes JA; Douglass J
    Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
    Neuzillet Y; Methorst C; Schneider M; Lebret T; Rouanne M; Radulescu C; Molinie V; Dreyfus JF; Pelcat V; Botto H
    Urol Oncol; 2014 Nov; 32(8):1135-40. PubMed ID: 25023786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.
    Sievert KD; Kruck S
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1055-63. PubMed ID: 19671025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
    Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
    BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation.
    Garfield SS; Gavaghan MB; Armstrong SO; Jones JS
    Can J Urol; 2013 Apr; 20(2):6682-9. PubMed ID: 23587507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
    Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
    Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
    Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
    J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
    Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
    J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.
    Geavlete B; Multescu R; Georgescu D; Geavlete P
    J Endourol; 2009 Jun; 23(6):977-81. PubMed ID: 19473068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.
    Palou J; Hernández C; Solsona E; Abascal R; Burgués JP; Rioja C; Cabrera JA; Gutiérrez C; Rodríguez O; Iborra I; Herranz F; Abascal JM; Conde G; Oliva J
    BJU Int; 2015 Jul; 116(1):37-43. PubMed ID: 25496450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hexvix induced fluorescence blue light cystoscopy--a new perspective in superficial bladder tumors diagnosis].
    Geavlete B; Mulţescu R; Georgescu D; Geavlete P
    Chirurgia (Bucur); 2008; 103(5):559-64. PubMed ID: 19260632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.